Neurocrine Biosciences Presents New Data Highlighting Functional and Socio-emotional Improvements with INGREZZA® (valbenazine) Capsules in Individuals with Tardive Dyskinesia and Intellectual and Developmental Disabilities
Neurocrine Biosciences presented new clinician-reported data at the American Academy of Developmental Medicine and Dentistry conference, highlighting functional and socio-emotional improvements in patients with tardive dyskinesia and intellectual disabilities. In a subgroup of 30 individuals, 89% experienced improvement in TD severity within four weeks of starting INGREZZA, and 96% of those with impaired baseline function showed overall functional status improvement.
Key figures
- Drug Name
- INGREZZA (valbenazine)
- Subgroup size
- 30
- Improvement rate 4 weeks
- 89%
- Mood disorder comorbidity
- 17%
- Schizophrenia comorbidity
- 70%
- Functional status improvement
- 96%
- Baseline td severity moderate severe
- 70%
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.